Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.

@article{Meininger2009GlatiramerAH,
  title={Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.},
  author={Vincent Meininger and Vivian Drory and Peter Nigel Leigh and Albert Ludolph and Wim Robberecht and Vincenzo Silani},
  journal={Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases},
  year={2009},
  volume={10 5-6},
  pages={378-83}
}
Our objective was to assess the efficacy and safety of 40 mg/day glatiramer acetate (GA) in patients with ALS. We conducted a double-blind, randomized, placebo-controlled, multicentre trial. Three hundred and sixty-six patients with definite, probable or probable laboratory supported ALS and a slow vital capacity > or = 70% were randomly assigned to treatment with placebo or 40 mg GA daily. The primary intention-to-treat analysis was the comparison between the two treated groups of the rates of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

Similar Papers

Loading similar papers…